Ocular Therapeutix: Positioning for a Positive SOL-1 Readout and Event-Driven Upside
Ocular Therapeutix (OCUL) looks like an asymmetric event trade. With AXPAXLI in large registrational programs, strong enrollment signals, rumors of renewed takeover interest from Sanofi, and stretched bearish sentiment, a positive SOL-1 readout could re-rate the stock. Risk is material - trial failure, financing needs, and reimbursement uncertainty…